<i>c‐Jun</i> amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme
Eric L. Snyder(University of Utah), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Christopher Fiore(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), Paola Dal Cin(Brigham and Women's Hospital), Joseph Brito(Dana-Farber Cancer Institute), Massimo Loda(Cornell University), D. R. Shackleton Bailey(Harvard University), Deborah J. Sandstrom(Brigham and Women's Hospital), Kenneth Law(Brigham and Women's Hospital), Jonathan A. Fletcher(Harvard University), Ewa Sicińska(Harvard University)
Cited by 87
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996